Management of Febrile Neutropenia
Initial Evaluation and Risk Stratification
- The American College of Physicians recommends obtaining blood cultures (two sets) from peripheral veins and all permanent catheters before starting antibiotics, without delaying treatment 1, 2
- Calculate the MASCC score immediately to determine treatment intensity: ≥21 indicates low risk and <21 indicates high risk 1
- High-risk patients include those with profound and prolonged expected neutropenia, acute leukemia, stem cell transplant, hypotension, organ failure, or pneumonia 1, 2
- Evaluate circulatory and respiratory function immediately, with vigorous resuscitation if necessary 2
Selection of Empiric Antibiotics
- The Infectious Diseases Society of America recommends starting intravenous monotherapy with piperacillin-tazobactam or cefepime as first-line treatment for high-risk patients 1, 2
- Carbapenems (meropenem or imipenem) are appropriate alternatives 3, 2
- Do not add vancomycin routinely, add it only if there are specific indications: catheter-related infection, cellulitis/skin and soft tissue infection, pneumonia, or hemodynamic instability 1, 2
Evaluation of Response to Treatment
- For afebrile patients with an absolute neutrophil count (ANC) ≥0.5 × 10⁹/L, consider switching to oral antibiotics 3, 2
- For patients with persistent fever at 48 hours, continue initial antibacterial therapy if clinically stable, or broaden antibiotic coverage and seek consultation with an infectious disease specialist if clinically unstable 3, 2
Management of Persistent Fever
- Start empiric antifungal therapy if fever persists for more than 4-6 days despite broad-spectrum antibiotics 3, 1, 2
- For presumed invasive aspergillosis (typical infiltrates on CT), voriconazole or liposomal amphotericin B are first-line options 3
Duration of Antibiotic Therapy
- Discontinue antibiotics if ANC ≥0.5 × 10⁹/L, patient is asymptomatic, afebrile for 48 hours, and blood cultures are negative 3, 1, 2
- If ANC ≤0.5 × 10⁹/L, continue antibiotics until ANC recovery or for at least 5-7 days if patient is afebrile and without complications 3, 1
Site-Specific Infection Management
- For central line infection, add vancomycin and administer through the line when possible 2
- For cellulitis, add vancomycin to broaden coverage against skin pathogens 2
- For candidosis, start fluconazole, with early switch to alternative antifungal if inadequate response 2